- Home
- PECO vs GH Comparison
PECO vs GH Comparison
Compare PECO & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PECO
- GH
- Stock Information
- Founded
- PECO 1991
- GH 2011
- Country
- PECO United States
- GH United States
- Employees
- PECO N/A
- GH N/A
- Industry
- PECO Real Estate Investment Trusts
- GH Medical Specialities
- Sector
- PECO Real Estate
- GH Health Care
- Exchange
- PECO Nasdaq
- GH Nasdaq
- Market Cap
- PECO 4.6B
- GH 4.9B
- IPO Year
- PECO 2021
- GH 2018
- Fundamental
- Price
- PECO $35.01
- GH $51.90
- Analyst Decision
- PECO Hold
- GH Strong Buy
- Analyst Count
- PECO 6
- GH 20
- Target Price
- PECO $37.60
- GH $54.35
- AVG Volume (30 Days)
- PECO 840.5K
- GH 2.3M
- Earning Date
- PECO 07-24-2025
- GH 08-06-2025
- Dividend Yield
- PECO 3.52%
- GH N/A
- EPS Growth
- PECO 19.02
- GH N/A
- EPS
- PECO 0.57
- GH N/A
- Revenue
- PECO $678,401,000.00
- GH $773,996,000.00
- Revenue This Year
- PECO $9.35
- GH $23.14
- Revenue Next Year
- PECO $6.56
- GH $21.42
- P/E Ratio
- PECO $60.75
- GH N/A
- Revenue Growth
- PECO 9.36
- GH 28.20
- 52 Week Low
- PECO $31.98
- GH $20.14
- 52 Week High
- PECO $40.12
- GH $53.42
- Technical
- Relative Strength Index (RSI)
- PECO 46.22
- GH 63.61
- Support Level
- PECO $34.42
- GH $47.45
- Resistance Level
- PECO $36.09
- GH $51.15
- Average True Range (ATR)
- PECO 0.62
- GH 2.29
- MACD
- PECO -0.08
- GH 0.05
- Stochastic Oscillator
- PECO 27.70
- GH 65.43
About PECO Phillips Edison & Company Inc.
Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interests, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on market of expertise designed to optimize property value and consistently deliver a great shopping experience.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.